On Friday, Zymeworks BC Inc (NASDAQ: ZYME) was 6.74% jump from the session before settling in for the closing price of $16.92. A 52-week range for ZYME has been $9.03 – $17.70.
Healthcare Sector giant saw their annual sales surged by 15.81% over the last five years. When this article was written, the company’s average yearly earnings per share was at 48.32%. With a float of $73.13 million, this company’s outstanding shares have now reached $74.85 million.
Zymeworks BC Inc (ZYME) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Zymeworks BC Inc stocks. The insider ownership of Zymeworks BC Inc is 3.44%, while institutional ownership is 102.24%. The most recent insider transaction that took place on May 15 ’25, was worth 565,847. In this transaction Director of this company bought 49,502 shares at a rate of $11.43, taking the stock ownership to the 17,877,989 shares. Before that another transaction happened on May 19 ’25, when Company’s Director bought 5,919 for $11.78, making the entire transaction worth $69,738. This insider now owns 17,883,908 shares in total.
Zymeworks BC Inc (ZYME) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.39 earnings per share (EPS) during the time that was better than consensus figure (set at -0.41) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 48.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.46% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
You can see what Zymeworks BC Inc (ZYME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.90 in one year’s time.
